Royalty Pharma plc (RPRX)
NASDAQ: RPRX · Real-Time Price · USD
63.60
-0.15 (-0.24%)
Oct 23, 2026, 11:24 AM EDT - Market open
Royalty Pharma Stock Forecast
Stock Price Forecast
According to 8 analysts polled by S&P Global, Royalty Pharma stock has a consensus rating of "Buy" and an average price target of $65.38. The average 1-year stock price forecast is 2.80% higher than the current stock price, while the lowest is $61 (-4.09%) and the highest is $70 (+10.06%).
Price Target: $65.38 (+2.80%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Royalty Pharma stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 5 | 5 | 5 |
| Buy | 3 | 2 | 2 | 2 | 2 | 2 |
| Hold | 1 | 2 | 2 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 10 | 10 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citi | Citi | Buy Maintains $70 | Buy | Maintains | $70 | +10.06% | Oct 12, 2026 |
| Bank of America Securities | Bank of America Securities | Buy Maintains $63 | Buy | Maintains | $63 | -0.94% | Oct 9, 2026 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $67 | Buy | Maintains | $67 | +5.35% | Oct 7, 2026 |
| TD Cowen | TD Cowen | Buy Reiterates $65 → $68 | Buy | Reiterates | $65 → $68 | +6.92% | Sep 8, 2026 |
| UBS | UBS | Buy Reiterates $66 | Buy | Reiterates | $66 | +3.77% | Sep 8, 2026 |
Financial Forecast
Revenue This Year
3.50B
from 2.38B
Increased by 47.38%
Revenue Next Year
3.82B
from 3.50B
Increased by 8.97%
EPS This Year
5.32
from 4.83
Increased by 10.18%
EPS Next Year
5.80
from 5.32
Increased by 8.98%
EPS and Forward PE are based on non-GAAP adjusted numbers.